Developer docs
API playgroundTry for free, no card

Search company profiles

NuCana

Full company profile

uuid0006c5j

Namestring
NuCana
Legal namestring
NuCana plc
Websiteurl
nucana.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

NuCana plc is a clinical-stage biopharmaceutical company headquartered in Edinburgh, UK, and listed on Nasdaq (ticker: NCNA). Founded in 2008 and operating with 11-50 employees, the company is developing a pipeline of anti-cancer medicines using its proprietary ProTide (phosphoramidate) chemistry platform, which is designed to transform widely prescribed nucleoside analog chemotherapy agents into more effective and safer drugs. The pipeline includes three clinical-stage candidates: NUC-7738 (in Phase 2 for melanoma and explored in renal cell carcinoma), NUC-3373 (a phosphoramidate modification of FUDR with over 300 patients dosed across four clinical studies, being explored in combination with pembrolizumab), and Acelarin/NUC-1031 (previously studied in Phase 3 biliary tract cancer, holding FDA Fast Track and Orphan Drug Designations from both FDA and EMA). NuCana is pre-revenue with no commercialized products; its business model is to advance candidates through clinical development toward regulatory approval and eventual commercialization or licensing. The company communicates clinical progress through scientific conference presentations (ESMO, AACR, ASCO), peer-reviewed publications, press releases, and investor relations activities.

The company has raised approximately $307 million cumulatively through a Series A ($11M, 2011), Series B ($57M, 2014, led by Sofinnova Ventures), Nasdaq IPO ($114M, October 2017), follow-on offering ($80M, 2020), and 2025 financings ($38M + $7M direct offering), with cash runway stated to extend into 2029. The intellectual property estate includes 389+ granted patents and 300+ pending applications, with composition-of-matter patents for NUC-7738 granted in the US (September 2024) and China (November 2025). Leadership includes founder/CEO Hugh Griffith (also an inventor on the patent estate and a prior acquisition executive at Bioenvision/Genzyme and Edixomed/Convatec), Chairman Andrew Kay (former Algeta CEO, sold to Bayer for $2.9 billion), and board representation from former senior executives at Amgen, Bristol-Myers Squibb, and Sanofi.

Short descriptiontext

NuCana plc is a clinical-stage biopharmaceutical company developing ProTide-based anti-cancer medicines, including candidates NUC-7738, NUC-3373, and Acelarin, using proprietary phosphoramidate chemistry to improve on conventional chemotherapy for oncology patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEdinburgh, United Kingdom
HQ citystring
Edinburgh
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, phosphoramidate chemistry, anti-cancer therapeutics, clinical-stage biopharmaceutical, nucleoside analog drugs
Industry1 code
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

NuCana is a pre-revenue clinical-stage biopharmaceutical company. The company is focused on developing its pipeline of ProTide-based anti-cancer medicines (NUC-7738, NUC-3373, Acelarin) through clinical trials with the goal of obtaining regulatory approval and commercializing products. No revenue has been generated from product sales as all candidates remain in clinical development.

nucana.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Acelarin
Description

A registered trademark of NuCana, a ProTide anti-cancer agent (also known as NUC-1031).

nucana.com
Core offering1 text field

NuCana is a clinical-stage biopharmaceutical company that develops anti-cancer medicines using its proprietary phosphoramidate (ProTide) chemistry platform. The company is advancing a pipeline of three drug candidates — NUC-7738, NUC-3373, and Acelarin (NUC-1031) — designed to transform widely prescribed chemotherapy agents into more effective and safer therapies for solid tumors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • NUC-7738 demonstrated clinical activity and favorable safety for patients with PD-1-resistant melanoma
+3 more records
Product overview1 text field

NuCana is a clinical-stage biopharmaceutical company with a platform-based approach, utilizing its proprietary ProTide (phosphoramidate) technology to transform widely prescribed chemotherapy agents into more effective and safer anti-cancer medicines. The company operates a pipeline of drug candidates including NUC-7738, NUC-3373, and Acelarin (NUC-1031), each developed using the ProTide platform to improve on existing nucleoside analog chemotherapy agents.

Product and service3 records
1NUC-7738
Categorydrug candidate
Description

Novel ProTide-based anti-cancer agent currently in Phase 2 clinical development for treatment of solid tumors, including PD-1-resistant metastatic melanoma. Designed to be more effective and safer than conventional chemotherapy and to potentiate PD-1 inhibitors such as pembrolizumab.

2NUC-3373
Categorydrug candidate
Description

Novel phosphoramidate modification of FUDR that generates high intracellular levels of FUDR-MP, producing potent thymidylate synthase inhibition, DNA damage, and cancer cell death. Over 300 patients with advanced solid tumors have received NUC-3373 across four clinical studies, including in second-line colorectal cancer and in combination with pembrolizumab.

3Acelarin (NUC-1031)
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Nuvation Bio
TypeDirect peer
Description

Clinical-stage oncology biopharmaceutical company developing differentiated therapeutic candidates across multiple cancer indications. Comparable as a similarly-sized, pre-revenue, publicly-traded oncology biotech with a multi-asset platform approach.

TypeDirect peer
Description

Clinical-stage oncology company developing immunotherapy combinations targeting PD-1 resistance and other immune evasion mechanisms. Highly comparable given the shared focus on overcoming PD-1 inhibitor resistance with novel combinations.

TypeDirect peer
Description

Clinical-stage immuno-oncology company using computational discovery to identify novel drug targets and develop first-in-class therapeutics. Comparable as a pre-revenue oncology biotech with a platform-based approach to address I/O resistance.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing cancer immunotherapies, including combinations targeting PD-1 pathways. Comparable as an I/O-focused clinical-stage biotech pursuing combination regimens in solid tumors.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing a novel class of bicyclic peptide-based therapeutics (Bicycles) for oncology. Comparable as a UK-headquartered clinical-stage oncology platform biotech with broad IP protection.

TypeDirect peer
Description

Clinical-stage biotechnology company developing precision therapies for genetically defined diseases including oncology indications. Comparable as a similarly-sized clinical-stage biotech focused on targeted oncology drug development.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecule therapies targeting the RAS/MAPK pathway. Comparable as a clinical-stage oncology platform with multiple candidates in development.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing targeted therapies for pediatric and adult cancers of high unmet need. Comparable as a clinical-stage oncology company advancing differentiated drug candidates through pivotal studies.

TypeDirect peer
Description

Clinical-stage oncology company applying a proprietary discovery platform to develop precision medicines against undrugged oncogenic drivers. Comparable as a clinical-stage biotech with platform technology generating multiple oncology candidates.

TypeBroad incumbent
Description

Clinical-stage oncology company (acquired by Bristol-Myers Squibb in 2024) that developed targeted oncology therapeutics including I/O combinations. Comparable as a historically relevant clinical-stage oncology peer at similar stage before its exit, providing relevant M&A benchmark for clinical-stage oncology biotechs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NuCana

Oncology Pharmaceuticalsnucana.com

NuCana plc is a clinical-stage biopharmaceutical company developing ProTide-based anti-cancer medicines, including candidates NUC-7738, NUC-3373, and Acelarin, using proprietary phosphoramidate chemistry to improve on conventional chemotherapy for oncology patients.

What NuCana does

NuCana plc is a clinical-stage biopharmaceutical company headquartered in Edinburgh, UK, and listed on Nasdaq (ticker: NCNA). Founded in 2008 and operating with 11-50 employees, the company is developing a pipeline of anti-cancer medicines using its proprietary ProTide (phosphoramidate) chemistry platform, which is designed to transform widely prescribed nucleoside analog chemotherapy agents into more effective and safer drugs. The pipeline includes three clinical-stage candidates: NUC-7738 (in Phase 2 for melanoma and explored in renal cell carcinoma), NUC-3373 (a phosphoramidate modification of FUDR with over 300 patients dosed across four clinical studies, being explored in combination with pembrolizumab), and Acelarin/NUC-1031 (previously studied in Phase 3 biliary tract cancer, holding FDA Fast Track and Orphan Drug Designations from both FDA and EMA). NuCana is pre-revenue with no commercialized products; its business model is to advance candidates through clinical development toward regulatory approval and eventual commercialization or licensing. The company communicates clinical progress through scientific conference presentations (ESMO, AACR, ASCO), peer-reviewed publications, press releases, and investor relations activities.

The company has raised approximately $307 million cumulatively through a Series A ($11M, 2011), Series B ($57M, 2014, led by Sofinnova Ventures), Nasdaq IPO ($114M, October 2017), follow-on offering ($80M, 2020), and 2025 financings ($38M + $7M direct offering), with cash runway stated to extend into 2029. The intellectual property estate includes 389+ granted patents and 300+ pending applications, with composition-of-matter patents for NUC-7738 granted in the US (September 2024) and China (November 2025). Leadership includes founder/CEO Hugh Griffith (also an inventor on the patent estate and a prior acquisition executive at Bioenvision/Genzyme and Edixomed/Convatec), Chairman Andrew Kay (former Algeta CEO, sold to Bayer for $2.9 billion), and board representation from former senior executives at Amgen, Bristol-Myers Squibb, and Sanofi.

NuCana firmographics

Firmographics
Name
NuCana
Legal name
NuCana plc
Website
https://nucana.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
NuCana plc is a clinical-stage biopharmaceutical company developing ProTide-based anti-cancer medicines, including candidates NUC-7738, NUC-3373, and Acelarin, using proprietary phosphoramidate chemistry to improve on conventional chemotherapy for oncology patients.
Ownership category
akta.pro rank

NuCana industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Oncology drug development
  • Phosphoramidate chemistry
  • Anti-cancer therapeutics
  • Clinical-stage biopharmaceutical
  • Nucleoside analog drugs

Where NuCana is headquartered

Location

Headquarters

HQ city
Edinburgh
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

NuCana business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Development and Commercialization: NuCana is a pre-revenue clinical-stage biopharmaceutical company. The company is focused on developing its pipeline of ProTide-based anti-cancer medicines (NUC-7738, NUC-3373, Acelarin) through clinical trials with the goal of obtaining regulatory approval and commercializing products. No revenue has been generated from product sales as all candidates remain in clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

NuCana product offering

Product offering

Core offering

NuCana is a clinical-stage biopharmaceutical company that develops anti-cancer medicines using its proprietary phosphoramidate (ProTide) chemistry platform. The company is advancing a pipeline of three drug candidates — NUC-7738, NUC-3373, and Acelarin (NUC-1031) — designed to transform widely prescribed chemotherapy agents into more effective and safer therapies for solid tumors.

Product overview

NuCana is a clinical-stage biopharmaceutical company with a platform-based approach, utilizing its proprietary ProTide (phosphoramidate) technology to transform widely prescribed chemotherapy agents into more effective and safer anti-cancer medicines. The company operates a pipeline of drug candidates including NUC-7738, NUC-3373, and Acelarin (NUC-1031), each developed using the ProTide platform to improve on existing nucleoside analog chemotherapy agents.

Differentiator

Problem solved

Functional benefit

Brands

  • Acelarin: A registered trademark of NuCana, a ProTide anti-cancer agent (also known as NUC-1031).

Products and services

  • NUC-7738 Novel ProTide-based anti-cancer agent currently in Phase 2 clinical development for treatment of solid tumors, including PD-1-resistant metastatic melanoma. Designed to be more effective and safer than conventional chemotherapy and to potentiate PD-1 inhibitors such as pembrolizumab.
  • NUC-3373 Novel phosphoramidate modification of FUDR that generates high intracellular levels of FUDR-MP, producing potent thymidylate synthase inhibition, DNA damage, and cancer cell death. Over 300 patients with advanced solid tumors have received NUC-3373 across four clinical studies, including in second-line colorectal cancer and in combination with pembrolizumab.
  • Acelarin (NUC-1031)

Quantifiable outcome

  • NUC-7738 demonstrated clinical activity and favorable safety for patients with PD-1-resistant melanoma
  • +3 more outcomes

Companies that use NuCana

Customer profile

Segments1 record

Ideal customer profiles2 records

NuCana technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

NuCana partnerships and signals

Strategic signal

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

NuCana competitors and assessment

Company assessment

Direct peers

  • Nuvation Bio: Clinical-stage oncology biopharmaceutical company developing differentiated therapeutic candidates across multiple cancer indications. Comparable as a similarly-sized, pre-revenue, publicly-traded oncology biotech with a multi-asset platform approach.
  • Tempest Therapeutics: Clinical-stage oncology company developing immunotherapy combinations targeting PD-1 resistance and other immune evasion mechanisms. Highly comparable given the shared focus on overcoming PD-1 inhibitor resistance with novel combinations.
  • Compugen: Clinical-stage immuno-oncology company using computational discovery to identify novel drug targets and develop first-in-class therapeutics. Comparable as a pre-revenue oncology biotech with a platform-based approach to address I/O resistance.
  • Arcus Biosciences: Clinical-stage biopharmaceutical company developing cancer immunotherapies, including combinations targeting PD-1 pathways. Comparable as an I/O-focused clinical-stage biotech pursuing combination regimens in solid tumors.
  • Bicycle Therapeutics: Clinical-stage biopharmaceutical company developing a novel class of bicyclic peptide-based therapeutics (Bicycles) for oncology. Comparable as a UK-headquartered clinical-stage oncology platform biotech with broad IP protection.
  • Cogent Biosciences: Clinical-stage biotechnology company developing precision therapies for genetically defined diseases including oncology indications. Comparable as a similarly-sized clinical-stage biotech focused on targeted oncology drug development.
  • Erasca: Clinical-stage precision oncology company developing small molecule therapies targeting the RAS/MAPK pathway. Comparable as a clinical-stage oncology platform with multiple candidates in development.
  • Day One Biopharmaceuticals: Clinical-stage biopharmaceutical company developing targeted therapies for pediatric and adult cancers of high unmet need. Comparable as a clinical-stage oncology company advancing differentiated drug candidates through pivotal studies.
  • Black Diamond Therapeutics: Clinical-stage oncology company applying a proprietary discovery platform to develop precision medicines against undrugged oncogenic drivers. Comparable as a clinical-stage biotech with platform technology generating multiple oncology candidates.

Broad incumbents

  • Mirati Therapeutics: Clinical-stage oncology company (acquired by Bristol-Myers Squibb in 2024) that developed targeted oncology therapeutics including I/O combinations. Comparable as a historically relevant clinical-stage oncology peer at similar stage before its exit, providing relevant M&A benchmark for clinical-stage oncology biotechs.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

NuCana social profiles

Digital presence

NuCana financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NuCana leadership team

Management profile

Number of profiles

Profiles11 records

NuCana funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NuCana M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NuCana

What does NuCana do?

NuCana is a clinical-stage biopharmaceutical company that develops anti-cancer medicines using its proprietary phosphoramidate (ProTide) chemistry platform. The company is advancing a pipeline of three drug candidates — NUC-7738, NUC-3373, and Acelarin (NUC-1031) — designed to transform widely prescribed chemotherapy agents into more effective and safer therapies for solid tumors.

Is NuCana a public or private company?

NuCana is a public company. It is classified as public and is currently operating.

When was NuCana founded?

NuCana was founded in 2008. It employs 11 to 50 people.

Where is NuCana based?

NuCana is headquartered in Edinburgh, United Kingdom, in the Europe region.

How does NuCana make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are NuCana's main competitors?

Direct peers on record are Nuvation Bio, Tempest Therapeutics, Compugen, Arcus Biosciences, Bicycle Therapeutics, Cogent Biosciences, Erasca, Day One Biopharmaceuticals and Black Diamond Therapeutics. Mirati Therapeutics is listed as a broad incumbent.

Does NuCana have an API?

No public API is recorded for NuCana.

What industry is NuCana in?

NuCana's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooNuCana Reports Second Quarter 2026 Financial Results and Provides Business UpdateNuCana plc announced its second quarter 2026 financial results and reported that patient recruitment is complete for the Phase 2 NuTide:701 expansion study evaluating NUC-7738 in combination with Keytruda for metastatic melanoma. The company expects final data from this study later in 2026 and confirmed a cash runway extending into 2029, providing flexibility to advance additional indications and combination strategies.Stock TitanNuCana names Ian Webster chief financial officerNuCana plc, a clinical-stage biopharmaceutical company, appointed Ian Webster as Chief Financial Officer effective June 1, 2026. Webster has served as Interim CFO since June 2025 and previously held the role of Director of Finance since joining the company in 2019, bringing over 20 years of finance experience including senior leadership roles at Kyowa Kirin International plc and PricewaterhouseCoopers LLP. The company noted its cash runway is anticipated to extend into 2029, with multiple data readouts expected in 2026 from its Phase 2 pipeline programs.GlobeNewswireNuCana Appoints Ian Webster as Chief Financial OfficerNuCana appointed Ian Webster as Chief Financial Officer, effective June 1, 2026, after serving as interim CFO since 2025. The company plans to generate data in 2026 from the Phase 2 NuTide:701 study and expects a cash runway into 2029.GlobeNewswireNuCana Reports Third Quarter 2025 Financial Results and Provides Business UpdateNuCana plc announced its third quarter 2025 financial results and provided an update on its clinical development programs for its anti-cancer medicines NUC-7738 and NUC-3373. The company presented encouraging data from its studies, including potential treatment benefits, and outlined milestones for upcoming data releases and regulatory discussions through 2026. NuCana also strengthened its financial position by raising capital, extending its cash runway into 2029.PharmiWeb.comNuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025NuCana plc presented data at the European Society for Medical Oncology Congress 2025 demonstrating that NUC-7738 synergizes with PD-1 inhibitors to enhance tumor cell killing in patient-derived organoids from renal cell carcinoma patients. The findings reinforce the drug's mechanism of action and support positive results from the ongoing Phase 1/2 NuTide:701 study, which has shown favorable safety, tumor volume reduction, and prolonged progression-free survival in PD-1 inhibitor-resistant melanoma patients. Regulators have approved expansion of the study to recruit 28 additional melanoma patients, and NuCana plans to meet with the FDA to discuss registration strategy for marketing approval.PharmiWeb.comNuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 TherapyNuCana plc announced new clinical data from the NuTide:303 study showing its drug NUC-3373 in combination with pembrolizumab demonstrated durable responses in heavily pre-treated patients with advanced solid tumors, including a metastatic melanoma patient who remained progression-free at 23 months and a bladder cancer patient with 100% tumor lesion reduction for over 15 months.GlobeNewswireNuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025NuCana will present data on NUC-7738's synergy with PD-1 inhibitors in renal cell cancer at the ESMO Congress 2025 in Berlin, October 17-21, 2025. The presentation, poster 1530P, uses patient-derived organoids to show the combination's effect. The company also highlights its pipeline, including NUC-7738 and NUC-3373.GlobeNewswireNuCana Prices $7 Million Registered Direct OfferingNuCana plc priced a registered direct offering of 10,845,985 ADSs with warrants, at a combined price of $0.6454 per unit. The offering is expected to generate approximately $7 million in gross proceeds, to be used for drug development and general corporate purposes. Closing is expected on or about May 7, 2025.GlobeNewswireNuCana Prices $7 Million Registered Direct OfferingNuCana plc priced a registered direct offering of 10,845,985 ADSs with warrants, at a combined price of $0.6454 per ADS. The offering is expected to generate approximately $7 million in gross proceeds, to be used for drug development and general corporate purposes. Closing is expected on or about May 7, 2025.